Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound|
|Abstract:||A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g., fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.|
|Inventor(s):||Kabadi; Mohan B. (Marlboro, NJ), Vivilecchia; Richard V. (Rockaway, NJ)|
|Assignee:||Sandoz Ltd. (Basel, CH)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Formulation; Dosage form; Delivery; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Hong Kong||25597||<disabled in preview>|
|Germany||4240430||<disabled in preview>|
|Germany||4245089||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.